Future studies will be required to determine the direct and indirect interactions of TOMM40, TOMM22, and BCAP31 with other proteins at MERCs that may impact adverse mitochondrial effects of statin treatment and predispose to the development of SAMS. The gene discussed is TOMM22; the disease is short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome.